Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Sponsor
Asociación para Evitar la Ceguera en México
Study ID
NCT00418431
Phase
PHASE2/PHASE3
Status
Withdrawn

Conditions

  • Central Serous Chorioretinopathy

Eligibility Criteria

Sex
ALL
Age
20 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment. The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.

Key Dates

First listed
Jan 4, 2007
Start date
Apr 30, 2006
Status verified
Jun 2024
Primary completion
Apr 30, 2006
Completion
Aug 31, 2006

Study Design

Enrollment
0 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Related Studies